FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893357650> ?p ?o ?g. }

• W2893357650 endingPage "49" @default.
• W2893357650 startingPage "44" @default.
• W2893357650 abstract "Potent platelet inhibition is one of the most important medical interventions to prevent ischemic complications during and after percutaneous coronary intervention (PCI). Practice has evolved with the introduction of potent oral P2Y12 inhibitors that provide quick, effective platelet inhibition, and the need for routine glycoprotein IIb/IIIa inhibitors (GPIs) has decreased. Additionally, a shorter duration of GPI infusion has been shown to be safe with adequate oral antiplatelet loading, but clinical outcome data are limited to eptifibatide. This single-center, retrospective cohort study analyzed in-hospital outcomes for patients who received adjunctive GPI therapy for PCI before and after an institution-wide switch to high-dose bolus tirofiban with shortened infusion from short-duration eptifibatide. The primary end point was a composite in-hospital outcome of major and minor bleeding and cardiovascular events (death, myocardial infarction, coronary artery bypass grafting, ischemic stroke, and target vessel revascularization). Secondary end points included bleeding and cardiovascular event types. A total of 357 and 446 patients received eptifibatide and tirofiban, respectively, from February 1, 2014 through September 30, 2017. Thirty five eptifibatide and 46 tirofiban patients experienced an in-hospital composite event (9.8% vs 10.3%, p = 0.81). There was no difference found between in-hospital bleeding (6.4% vs 5.4%, p = 0.52) or cardiovascular events (5.6% vs 6.5%, p = 0.60) with the use of eptifibatide or tirofiban, respectively. Multivariable analysis showed that patients with transradial access or an indication of unstable angina were less likely to experience an in-hospital composite event (OR 0.30 and 0.19, respectively, p <0.001 for both). In conclusion, the use of high-dose bolus tirofiban with shortened infusion versus short-duration eptifibatide was not associated with an increase of in-hospital bleeding or cardiovascular events. Potent platelet inhibition is one of the most important medical interventions to prevent ischemic complications during and after percutaneous coronary intervention (PCI). Practice has evolved with the introduction of potent oral P2Y12 inhibitors that provide quick, effective platelet inhibition, and the need for routine glycoprotein IIb/IIIa inhibitors (GPIs) has decreased. Additionally, a shorter duration of GPI infusion has been shown to be safe with adequate oral antiplatelet loading, but clinical outcome data are limited to eptifibatide. This single-center, retrospective cohort study analyzed in-hospital outcomes for patients who received adjunctive GPI therapy for PCI before and after an institution-wide switch to high-dose bolus tirofiban with shortened infusion from short-duration eptifibatide. The primary end point was a composite in-hospital outcome of major and minor bleeding and cardiovascular events (death, myocardial infarction, coronary artery bypass grafting, ischemic stroke, and target vessel revascularization). Secondary end points included bleeding and cardiovascular event types. A total of 357 and 446 patients received eptifibatide and tirofiban, respectively, from February 1, 2014 through September 30, 2017. Thirty five eptifibatide and 46 tirofiban patients experienced an in-hospital composite event (9.8% vs 10.3%, p = 0.81). There was no difference found between in-hospital bleeding (6.4% vs 5.4%, p = 0.52) or cardiovascular events (5.6% vs 6.5%, p = 0.60) with the use of eptifibatide or tirofiban, respectively. Multivariable analysis showed that patients with transradial access or an indication of unstable angina were less likely to experience an in-hospital composite event (OR 0.30 and 0.19, respectively, p <0.001 for both). In conclusion, the use of high-dose bolus tirofiban with shortened infusion versus short-duration eptifibatide was not associated with an increase of in-hospital bleeding or cardiovascular events." @default.
• W2893357650 created "2018-10-05" @default.
• W2893357650 creator A5003923483 @default.
• W2893357650 creator A5008644265 @default.
• W2893357650 creator A5018137894 @default.
• W2893357650 creator A5024247297 @default.
• W2893357650 creator A5024567376 @default.
• W2893357650 creator A5054056429 @default.
• W2893357650 creator A5057339845 @default.
• W2893357650 date "2019-01-01" @default.
• W2893357650 modified "2023-09-26" @default.
• W2893357650 title "Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention" @default.
• W2893357650 cites W1543792369 @default.
• W2893357650 cites W159217275 @default.
• W2893357650 cites W1914615055 @default.
• W2893357650 cites W1990018236 @default.
• W2893357650 cites W2017958214 @default.
• W2893357650 cites W2059484871 @default.
• W2893357650 cites W2086993538 @default.
• W2893357650 cites W2095444271 @default.
• W2893357650 cites W2139834809 @default.
• W2893357650 cites W2149011208 @default.
• W2893357650 cites W2166905943 @default.
• W2893357650 cites W2168079615 @default.
• W2893357650 cites W2171098433 @default.
• W2893357650 cites W2281862598 @default.
• W2893357650 cites W2313726388 @default.
• W2893357650 cites W2318539064 @default.
• W2893357650 cites W2472400593 @default.
• W2893357650 cites W2499903992 @default.
• W2893357650 cites W2624916373 @default.
• W2893357650 cites W4237482550 @default.
• W2893357650 cites W4237892021 @default.
• W2893357650 cites W4256202725 @default.
• W2893357650 cites W4293372203 @default.
• W2893357650 doi "https://doi.org/10.1016/j.amjcard.2018.09.029" @default.
• W2893357650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30539747" @default.
• W2893357650 hasPublicationYear "2019" @default.
• W2893357650 type Work @default.
• W2893357650 sameAs 2893357650 @default.
• W2893357650 citedByCount "2" @default.
• W2893357650 countsByYear W28933576502020 @default.
• W2893357650 countsByYear W28933576502021 @default.
• W2893357650 crossrefType "journal-article" @default.
• W2893357650 hasAuthorship W2893357650A5003923483 @default.
• W2893357650 hasAuthorship W2893357650A5008644265 @default.
• W2893357650 hasAuthorship W2893357650A5018137894 @default.
• W2893357650 hasAuthorship W2893357650A5024247297 @default.
• W2893357650 hasAuthorship W2893357650A5024567376 @default.
• W2893357650 hasAuthorship W2893357650A5054056429 @default.
• W2893357650 hasAuthorship W2893357650A5057339845 @default.
• W2893357650 hasConcept C126322002 @default.
• W2893357650 hasConcept C164705383 @default.
• W2893357650 hasConcept C2776335557 @default.
• W2893357650 hasConcept C2777565915 @default.
• W2893357650 hasConcept C2777849778 @default.
• W2893357650 hasConcept C2777871224 @default.
• W2893357650 hasConcept C2780400711 @default.
• W2893357650 hasConcept C2781056559 @default.
• W2893357650 hasConcept C35294091 @default.
• W2893357650 hasConcept C42219234 @default.
• W2893357650 hasConcept C45393284 @default.
• W2893357650 hasConcept C500558357 @default.
• W2893357650 hasConcept C71924100 @default.
• W2893357650 hasConceptScore W2893357650C126322002 @default.
• W2893357650 hasConceptScore W2893357650C164705383 @default.
• W2893357650 hasConceptScore W2893357650C2776335557 @default.
• W2893357650 hasConceptScore W2893357650C2777565915 @default.
• W2893357650 hasConceptScore W2893357650C2777849778 @default.
• W2893357650 hasConceptScore W2893357650C2777871224 @default.
• W2893357650 hasConceptScore W2893357650C2780400711 @default.
• W2893357650 hasConceptScore W2893357650C2781056559 @default.
• W2893357650 hasConceptScore W2893357650C35294091 @default.
• W2893357650 hasConceptScore W2893357650C42219234 @default.
• W2893357650 hasConceptScore W2893357650C45393284 @default.
• W2893357650 hasConceptScore W2893357650C500558357 @default.
• W2893357650 hasConceptScore W2893357650C71924100 @default.
• W2893357650 hasFunder F4320306143 @default.
• W2893357650 hasIssue "1" @default.
• W2893357650 hasLocation W28933576501 @default.
• W2893357650 hasLocation W28933576502 @default.
• W2893357650 hasOpenAccess W2893357650 @default.
• W2893357650 hasPrimaryLocation W28933576501 @default.
• W2893357650 hasRelatedWork W103736013 @default.
• W2893357650 hasRelatedWork W2025299301 @default.
• W2893357650 hasRelatedWork W2058971526 @default.
• W2893357650 hasRelatedWork W2066237471 @default.
• W2893357650 hasRelatedWork W2163292105 @default.
• W2893357650 hasRelatedWork W2378796272 @default.
• W2893357650 hasRelatedWork W2552017037 @default.
• W2893357650 hasRelatedWork W2740454508 @default.
• W2893357650 hasRelatedWork W2786817769 @default.
• W2893357650 hasRelatedWork W45326695 @default.
• W2893357650 hasVolume "123" @default.
• W2893357650 isParatext "false" @default.
• W2893357650 isRetracted "false" @default.
• W2893357650 magId "2893357650" @default.
• W2893357650 workType "article" @default.